Clinical Investigators Beware: Greater FDA Review

Law360, New York (February 17, 2010, 2:04 PM EST) -- While it is common knowledge that the U.S. Food and Drug Administration is being more active in its review of prescription drug advertising by drug product manufacturers, it may not be widely known that the FDA is reviewing what clinical investigators are stating about drugs for which they served as an investigator and which are not yet FDA-approved.

Recently, the FDA posted on its Web site a Notice of Violation Letter sent Jan. 11, 2010, to Dr. Leslie Baumann of the Baumann Cosmetic and Research Institute....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.